COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
31/12/2025
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of [...]
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
31/12/2025
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a [...]
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
31/12/2025
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026. BioAtla to retain 65% [...]
SAFE : Assemblée Générale - Approbation de l’ensemble des résolutions
31/12/2025
SAFE Assemblée Générale du 26 décembre 2025 Approbation de l’ensemble des résolutions Fleurieux-sur-l’Arbresle - France - le 31 décembre 2025 à 8h . L’assemblée générale des actionnaires de Safe réunie le 26 décembre [...]
Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study
31/12/2025
Industry Analysis Examines How Cost-Conscious Patients Navigate GLP-1 Options After FDA Oral Semaglutide Approval — Platform Verification Methods, Compounded Medication Regulatory Status, and Third-Party Certification [...]
Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands
31/12/2025
Complete Pricing Comparison Shows FDA-Approved Wegovy Access From $149 Oral to Ro's $199 Injectable Through Telehealth as 1 in 8 Americans Now Use GLP-1 Medications NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Disclaimer [...]
Positron Corporation Raises $2 Million to Expand Market Presence and Growth Initiatives
30/12/2025
Buffalo, NY, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (OTC: POSC) (the “Company”), a leading molecular imaging medical device company specializing in Positron Emission Tomography (PET) and PET-CT imaging [...]
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
30/12/2025
SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Medline Announces Participation in J.P. Morgan 2026 Healthcare Conference
30/12/2025
NORTHFIELD, Ill., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at [...]
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
30/12/2025
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa NOVATO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has [...]
PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference
30/12/2025
MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 44th [...]
Treace to Present at 44th Annual J.P. Morgan Healthcare Conference
30/12/2025
PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy
30/12/2025
Terah Krigsvold to replace Andrea Goren as CFO, who is named chief business officer and CEO of INVO Centers LLC to focus on growth efforts SARASOTA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: [...]
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
30/12/2025
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Profound Medical Corp. Announces Closing of Private Placement
30/12/2025
TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common [...]
AIM ImmunoTech Announces Stock Dividend
30/12/2025
OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common [...]
Cannabix Secures First Distributor Order for BreathLogix Alcohol Screening Devices in Australia
30/12/2025
Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings VANCOUVER, British Columbia, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies [...]
iSpecimen Inc. Announces Pricing of ~$5.5 Million Private Placement
30/12/2025
WOBURN, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
30/12/2025
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the [...]

Pages